A 20-year perspective on the development of non-cancer risk assessment methods

Human and Ecological Risk Assessment

Volumn 9, Issue 5, 2003, Pages 1239-1252

  Dourson, Michael ^a   Patterson, Jacqueline ^a  

^a Toxicology Excellence for Risk Assessment   (United States)

Author keywords

Cancer risk; National Research Council; Non cancer risk; Red Book; Risk assessment; Safety factors

Indexed keywords

EID: 2342478627     PISSN: 10807039     EISSN: None     Source Type: Journal    
DOI: 10.1080/10807030390247213     Document Type: Review

References (55)

1. Abdel-Rahman MS and Kadry AM. 1995. The use of uncertainty factors in deriving RfDs: an overview. Human Ecol Risk Assess 1 (5):614-25
2. Allen BC, Kavlock RJ, Kimmel CA, et al. 1994a. Dose-response assessment for developmental toxicity. II. Comparison of generic benchmark dose estimates with no observed adverse effect levels. Fund Applied Toxicol 23(4):487-95
3. Allen BC, Kavlock RJ, Kimmel CA, et al. 1994b. Dose-response assessment for developmental toxicity. III. Statistical Models. Fund Applied Toxicol 23 (4):496-509
4. Baird SJS, Cohen JT, Graham JD, et al. 1996. Noncancer risk assessment: probabilistic characterization of population threshold doses. Human Ecol Risk Assess 2(1):79-102
5. Barnes DG and Dourson ML. 1988. Reference dose (RfD): description and use in health risk assessment. Regul Toxicol Pharmacol 8:471-86
6. Crump KS. 1984. A new method for determining allowable daily intakes. Fund Appl Toxicol 4:854-71
7. Crump KS. 1995. Calculation of benchmark doses from continuous data. Risk Anal 15:79-90
8. Crump KS, Kjellstrom T, Shipp AM, et al. 1998. Influence of prenatal mercury exposure upon scholastic and psychological test performance: Benchmark analysis of a New Zealand cohort. Risk Anal 18(6):701-13
9. Dourson ML. 1994. Methods for establishing oral reference doses (RfDs). In: Merts W, Abernathy CO, and Olin SS (eds), Risk Assessment of Essential Elements, pp 51-61. ILSI Press, Washington, DC, USA
10. Dourson ML and Stara JF. 1983. Regulatory history and experimental support of uncertainty (safety) factors. Reg Toxicol Pharmacol 3:224-38
11. Dourson ML, Hertzberg RC, Hartung R, et al. 1985. Novel approaches for the estimation of acceptable daily intake. Toxicol Ind Health 1 (4):23-41
12. Dourson ML, Felter SP, and Robinson D. 1996. Evolution of science-based uncertainty factors in noncancer risk assessment. Regul Toxicol Pharmacol 24:108-20
13. Dourson ML, Maier A, Meek B, et al. 1998. Re-evaluation of toxicokinetics for data-derived uncertainty factors. Biol Trace Element Res 66(1-3):453-63
14. EPA (US Environmental Protection Agency). 1986. Guidelines for carcinogen risk assessment. 51 Fed Regist 33992:1-17
15. EPA (US Environmental Protection Agency). 1991. Guidelines for Developmental Toxicity Risk Assessment. Fed Regist 56(234):63798-826. December 5
16. EPA (US Environmental Protection Agency). 1994. Guidelines for Reproductive Toxicity Risk Assessment. Review Draft. EPA/600/AP-94/001. Office of Research and Development, Washington, DC, USA. February
17. EPA (US Environmental Protection Agency). 1995. The Use of the Benchmark Dose Approach in Health Risk Assessment. EPA/630/R-94/007. Risk Assessment Forum, Washington, DC, USA. February
18. EPA (US Environmental Protection Agency). 1996. Proposed Guidelines for Carcinogen Risk Assessment. Office of Research and Development. EPA/600/P-92/003C. Washington, DC, USA. April
19. EPA (US Environmental Protection Agency). 1998. Catreg Software User Manual. USEPA/ 600/R-98/052. Office of Research and Development, Washington, DC, USA
20. EPA (US Environmental Protection Agency). 1998. Guidelines For Neurotoxicity Risk Assessment. USEPA 630/R-95/001f. 30 April 1998. Risk Assessment Forum, Washington, DC, USA
21. EPA (US Environmental Protection Agency). 2002. A Review of the Reference Dose (RfD) and Reference Concentration (RfC) Processes. Final Report. EPA/630/Patricia-02/002F. Risk Assessment Forum, Washington, DC, USA. December
22. EPA (US Environmental Protection Agency). 2003. Integrated Risk Information System. Office of Research and Development. Washington, DC, USA. Available at: http://www. epa.gov/iris
23. Felter SP and Dourson M. 1998. The inexact science of risk assessment (and implications for risk management). Human Ecol Risk Assessment 2:245-51
24. Gaylor DW and Slikker W. 1990. Risk assessment for neurotoxic effects. NeuroToxicology 11:211-8
25. Guth DJ, Jarabek AM, Wymer L, and Hertzberg RC. 1991. Evaluation of risk assessment methods for short-term inhalation exposure. Presented at the 4th annual meeting of the Air and Waste Management Association, Vancouver, British Columbia, June 16-21.
26. Guth DJ, Carroll RJ, Simpson DG, et al. 1997. Categorical regression analysis of acute exposure to tetrachloroethylene. Risk Anal 17(3):321-32
27. Haines RG. 1971. Ingestion of aldicarb by human volunteers: A controlled study of the effect of aldicarb on man. Unpublished report in USEPA pesticide petition No. 1F1008. US Environmental Protection Agency, Washington, DC, USA
28. Hertzberg RC. 1989. Fitting a model to categorical response data with application to species extrapolation of toxicity. Health Physics 57:405-9
29. Hertzberg RC and Miller M. 1985. A statistical model for species extrapolation using categorical response data. Tox Ind Health 1:43-57
30. IPCS (International Programme on Chemical Safety). 1994. Derivation of Guidance Values for Health-Based Exposure Limits. Environmental Health Criteria No. 170: Assessing Human Health Risks of Chemicals. World Health Organization, Geneva, Switzerland
31. IPCS (International Programme on Chemical Safety). 1998. Boron. Environmental Health Criteria, vol. 204. World Health Organization, Geneva, Switzerland
32. IPCS (International Programme on Chemical Safety). 2001. Guidance Document for the use of Chemical-Specific Adjustment Factors (CSAF). Geneva. Switzerland. Available at http://www.ipcsharmonize. org/
33. Jarabek AM. 1994. Inhalation RfC methodology: dosimetric adjustments and dose-response estimation of noncancer toxicity in the upper respiratory tract. Inhal Toxicol 6 (suppl):301-25
34. Kadry AM, Skowronski GA, and Abdel-Rahman MS. 1995. Evaluation of the use of uncertainty factors in deriving RfDs for some chlorinated compounds. J Toxicol Environ Health 45:83-95
35. Kalberlah F and Schneider K. 1998. Quantification of extrapolation factors. Final report of the research project No. 116 06 113. Federal Environmental Agency (Umweltbundesamt), Berlin, Germany.
36. Kavlock RJ, Allen BC, Faustman EM, et al. 1995. Dose-response assessments for developmental toxicity. IV. Benchmark doses for fetal weight changes. Fundam Appl Toxicol 26:496-509
37. Kroes R, Munro I, and Poulsen E. 1993. Scientific evaluation of the safety factor for the acceptable daily intake. Food Addit Contam 10(3):269-373
38. Meek ME, Newhook R, Liteplo RG, et al. 1994. Approach to assessment of risk to human health for priority substances under the Canadian Environmental Protection Act. Environ Carcinogenesis Ecotoxicol Rev C12(2):105-34
39. Meek B, Renwick A, Ohanian E, et al. 2001. Guidelines for application of compound specific adjustment factors (CSAF) in dose/concentration response assessment. Comments on Toxicology 7(5/6):575-90
40. Naumann BD and Weideman PA. 1995. Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients. Human Ecol Risk Assess 1(5):590-613
41. Naumann BD, Weideman PA, Dixit R, et al. 1997. Use of toxicokinetic and toxicodynamic data to reduce uncertainties when setting occupational exposure limits for pharmaceuticals. Human Ecol Risk Assess 3(4):555-65
42. NRC (National Research Council). 1983. Risk Assessment in the Federal Government: Managing the Process. National Academy Press, Washington, DC, USA
43. Pohl HR and Abadin HG. 1995. Utilizing uncertainty factors in minimal risk levels derivation. Regul Toxicol Pharmacol 22:180-8
44. Pohl HR, Smith-Simon C, and Hicks H. 1998. Health effects classification and its role in the derivation of minimal risk levels: Developmental effects. Regul Toxicol Pharmacol 28:55-60.
45. Price B, Berner T, Henrich RT, et al. 1996. A benchmark concentration for carbon disulfide: analysis of the NIOSH carbon disulfide exposure database. Regul Toxicol Pharmacol 24:171-6
46. Price PS, Keenan RE, Swartout JC, et al. 1997. An approach for modeling noncancer dose responses with an emphasis on uncertainty. Risk Anal 17(4):427-37
47. Rademaker BC and Linders JBHJ. 1994. Progress Report 3: Estimated-concentrations-of-no-concern of polluting agents in drinking water and air for humans
48. Renwick AG. 1991. Safety factors and establishment of acceptable daily intakes. Food Addit Contam 8(2):135-50
49. Renwick AG. 1993. Data derived safety factors for the evaluation of food additives and environmental contaminants. Food Addit Contam 10(3):275-305
50. Renwick AG and Lazarus NR. 1998. Human variability and Noncancer risk assessment - an analysis of the default uncertainty factor. Regul Toxicol Pharmacol 27:3-20 National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands. May
51. Renwick AG and Walker R. 1993. An analysis of the risk of exceeding the acceptable or tolerable daily intake. Regul Toxicol Pharmacol 18:463-80
52. Skowronski GA, Kadry AM, and Abdel-Rahman MS. 1995. Investigating the use of 10X uncertainty factors in health risk assessment of metals. Human Ecol Risk Assess 1(5):544-55
53. Swartout JC, Price PS, Dourson ML, et al. 1998. A probabilistic framework for the reference dose. Risk Anal 18(3):271-82
54. TERA (Toxicology Excellence for Risk Assessment). 2003. International Toxicity Estimates for Risk (ITER) database. Cincinnati, Ohio. Available at www.TERA.org/iter
55. Wyld PJ, Watson CE, and Nimmo WS. 1992. A Safety and Tolerability Study of Aldicarb at Various Dose Levels in Healthy Male and Female Volunteers. Study submitted to USEPA by Rhone-Poulenc Company. In: Sette WF, Memorandum: Joint OPPT/OW/ORD Review of 1992 Aldicarb Human Study. US Environmental Protection Agency, Washington, DC, USA. September 4